LBA2Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve ALK+ advanced non-small-cell lung cancer (NSCLC)
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI